Quality of life among patients with stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: Results from cancer and group B 9066 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Marrow Transplantation
  • Breast Neoplasms
  • Quality of Life

abstract

  • Patients who received more intensive adjuvant therapy experienced transient declines in QOL. By 12 months after therapy, QOL was comparable between the 2 arms, regardless of therapy intensity, and many QOL areas were improved from baseline.

publication date

  • October 15, 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.21363

PubMed ID

  • 16118805

Additional Document Info

start page

  • 1580

end page

  • 9

volume

  • 104

number

  • 8